anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our proposed TOGA wil consist of portions of the PACE and some additional screening tools, and will be applied prospectively to all patients 70 years old and above seen in the UWCCC for a thoracic oncology surgery. Residents of nursing homes and assisted living facilities will be eligible for this study if they are thought to be appropriate surgical candidates; other institutionalized patients will not. The preoperative TOGA will be performed by either Drs. Weigel, Maloney, LoConte or Traynor or P.A. Block. The TOGA includes parts of the PACE, involving assessment of co-morbid illness, Activities of Daily Living \[ADL\], Instrumental Activities of Daily Living \[IADL\], Geriatric Depression Screen \[GDS\], Brief Fatigue Inventory \[BFI\], Eastern Cooperative Oncology Group/Zubrod Performance Status \[PS\], Mini Mental State Exam (MMSE), in addition to an American Society of Anesthesiologists Score\[ASA\] and mini nutritional assessment (MNA), which were not done in the PACE. The TOGA should take up to 25 minutes to complete (Audisio, 2006), and will be done at only one time preoperativelOur hypothesis is that this novel, preoperative Thoracic Onco Geriatric Assessment (TOGA) will serve to predict outcomes for older patients going though thoracic oncology surgery, and thus will enhance geriatric patient care through the development of concise, validated, preoperative risk stratification.

Our hypothesis is that this abbreviated geriatric screening tool will be a better predictor for surgical and oncologic complications after surgery than performance status alone (which is currently the only measure of fitness used in routine oncology care). In addition, we predict that parts of the TOGA, specifically the instrumental activites of daily living score (IADL), mini nutritional assessment (MNA) and the brief fatigue inventory (BFI), will be the strongest predictor(s) of outcomes in our thoracic surgery population. The outcomes data we generate will also be important in quality improvement and standardization of preoperative risk assessment for elderly patients with thoracic malignancies.
The patients included in the strength exercise group performed weight training exercises involving 10 large muscle groups (leg press, chest press, leg curl, lateral pull down, leg extension, dumbbell lateral raise, calf press, upright row, sit up, quadruped arm opposite leg raise), 3 days a week; including 1 set of 12-15 repetitions in the first month, 2 sets of 12-15 repetitions in the second month, and 3 sets of 12-15 repetitions in the third month (Figure 1). Participants' working weights were set as 60% of the maximum weight they could lift.
FIELD: medicine. ^ SUBSTANCE: live attenuated Pasteurella multocida bacterium is modified by introduing a mutation into the gene Orf-15. The mutation represents insertion and/or deletion in the gene Orf-15. As a result of modification, the bacterium is not able to express the functional protein Orf-15 that leads to its attenuation. Also, disclosed is the use of such bacterium for preparing a related vaccine for human or animal protection against Pasteurella multocida bacteria infection or pathogenic effects of the infection. ^ EFFECT: increased efficacy of applying the composition. ^ 16 cl, 1 dwg, 3 tbl, 6 ex
All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
The current application comes to present a new method to disable the vital functions of tumor cells and thereby prevent their growth and systemic damage, given the excessive appetite for glucose that these types of cells have in their entirety and that is determined by the energy paradigm, which bases its energy production on fermentation, a less efficient process. The method is based on binding iron to a known structural analogue of glucose and already used inside tumor cells, such as 2-deoxyglucose, to give the molecule magnetic capacity, and bismuth to provide diamagnetic capacity. In a non-toxic solution, both molecules are integrated in the proportion already described and they enter the blood flow, as close as possible to where the tumor cells are located. Once inside them, the application of variable non-ionizing magnetic fields begins. , out of phase and discontinuous, so that the kinetic energy derived from these cyclical and continuous movements ends up disabling vital functions of this type of cell, or the saturation of carbohydrate receptors itself. Likewise, protection is requested for the two new molecules created in the development of this method, object of the current invention patent.  (Machine-translation by Google Translate, not legally binding)
Fosamprenavir calcium tablets may be taken with or without food.

Adults should take fosamprenavir calcium oral suspension without food. Pediatric patients should take fosamprenavir calcium oral suspension with food [see Clinical Pharmacology (12.3)]. If emesis occurs within 30 minutes after dosing, re-dosing of fosamprenavir calcium oral suspension should occur.

Higher-than-approved dose combinations of fosamprenavir calcium tablets plus ritonavir are not recommended due to an increased risk of transaminase elevations [see Overdosage (10)].

When fosamprenavir calcium tablets are used in combination with ritonavir, prescribers should consult the full prescribing information for ritonavir.
BACKGROUND: Among patients with heart failure (HF), fatigue is common and linked to quality of life and functional status. Fatigue is hypothesized to manifest as multiple types, with general and exertional components. Unique subtypes of fatigue in HF may require differential assessment and treatment to improve outcomes. We conducted this study to identify fatigue subtypes in persons with prevalent HF in the ARIC study (Atherosclerosis Risk in Communities) and describe the distribution of characteristics across subtypes.
METHODS: We performed a cross-sectional analysis of 1065 participants with prevalent HF at ARIC visit 5 (2011-2013). We measured exertional fatigue using the Modified Medical Research Council Breathlessness scale and general fatigue using the Patient Reported Outcomes Measurement Information System fatigue scale. We used latent class analysis to identify subtypes of fatigue. Number of classes was determined using model fit statistics, and classes were interpreted and assigned fatigue severity rating based on the conditional probability of endorsing survey items given class. We compared characteristics across classes using multinomial regression.
RESULTS: Overall, participants were 54% female and 38% Black with a mean age of 77. We identified 4 latent classes (fatigue subtypes): (1) high general/high exertional fatigue (18%), (2) high general/low exertional fatigue (27%), (3) moderate general/moderate exertional fatigue (20%), and (4) low/no general and exertional fatigue (35%). Female sex, Black race, lower education level, higher body mass index, increased depressive symptoms, and higher prevalence of diabetes were associated with higher levels of general and exertional fatigue.
CONCLUSIONS: We identified unique subtypes of fatigue in patients with HF who have not been previously described. Within subtype, general and exertional fatigue were mostly concordant in severity, and exertional fatigue only occurred in conjunction with general fatigue, not alone. Further understanding these fatigue types and their relationships to outcomes may enhance our understanding of the symptom experience and inform prognostication and secondary prevention efforts for persons with HF.
The invention relates to a traditional Chinese medicine for treating climacteric syndrome of women. The traditional Chinese medicine comprises the following components by weight: 10-20g of prepared rehmannia root, 10-20g of semen boitae, 10-20g of dogwood, 10-15g of fried spina date seed, 10-15g of uncaria, 10-15g of herba epimedii, 10-15g of radix paeoniae alba, 10-15g of Angelica sinensis, 15-25g of calcined ossa draconis, 15-25g of calcined oyster shell, 20-30g of Chinese yam, 20-30g of light wheat, 5-12g of radix bupleuri, 5-12g of Scutellaria baicalensis, 5-12g of the fruit of Chinese wolfberry, 5-10g of golden cypress, 1-3g of Schisandra chinensis and 5-10g of liquorice. The traditional Chinese medicine for treating climacteric syndrome of women provided by the invention is a traditional Chinese medicine summarized and optimized by long-range research of people. The traditional Chinese medicine is reasonable in component, simple to prepare and convenient to take. Clinical application for many years verifies that the traditional Chinese medicine is remarkable in curative effect, mild in property and free from toxic and side effects. The effective rate is 90% and the cure rate is 80%.
Subjects in the control group will be invited to participate in more conventional exercise sessions, based on a fitness and mobility exercise (FAME) program, 60-minute per sessions twice a week for 12 weeks. One additional session (60 minutes) per week, in autonomy, at home, will be recommended and accompanied by a video support. The effectiveness of this program has already been demonstrated in previous studies.
Age 50-75, men or women, smokers or non-smokers. Being first degree relatives (siblings, children and parents) of lung cancer subjects. Having no known lung cancer before.
Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
The invention belongs to the technical field of medicines, and discloses application of osthole and derivatives thereof in inhibiting aldehyde ketone reductase. Specifically, osthole and derivatives or pharmaceutically acceptable salts thereof can obviously inhibit the activity of aldehyde ketone reductase. The aldehyde ketone reductase is AKR1C 3. The osthole and the derivatives thereof can selectively inhibit the activity of aldehyde ketone reductase 1C3, and have obvious inhibition effect. The invention also provides application of osthole and derivatives or pharmaceutically acceptable salts thereof in preparing medicines for inhibiting aldehyde ketone reductase 1C 3. The osthole and the derivatives thereof inhibit the final step of androgen production in tumor cells by inhibiting the activity of aldehyde ketone reductase 1C3, thereby achieving the effect of preventing and treating prostate cancer.
BACKGROUND: Chronic kidney disease (CKD) and overweight/obesity are significant global public health issues. Appropriate free-time physical activity (PA) is essential for overweight/obese patients with chronic kidney disease, but specific guidelines are lacking. The present study was conducted to determine the association between PA and all-cause mortality in these patients.
METHODS: Data from 3,434 overweight/obese adults with CKD from the 1999-2016 National Health and Nutrition Examination Surveys were analyzed. Associations between clinical/laboratory findings and PA intensity (moderate and vigorous) were investigated. The all-cause mortality of patients in different PA categories were compared by Kaplan-Meier analysis. Factors associated with all-cause mortality were determined using a Cox proportional hazards model. A restricted cubic spline was employed to obtain a more flexible and detailed representation of the relationship between PA intensity and all-cause mortality, with better predictive capability.
RESULTS: The Kaplan-Meier analysis revealed that greater all-cause mortality was associated with < 10 min/week moderate/vigorous PA (log-rank p < 0.001). A greater survival probability was associated with ≥ 150 min/week vigorous PA or 10-149 min/week moderate PA (log-rank p < 0.001). Age, gender, vigorous PA, smoking status, alcohol consumption, diabetes status, eGFR, serum albumin level, uric acid level, and blood urea nitrogen level were identified as factors associated independently with mortality in the Cox proportional hazards analysis. The restricted cubic splines revealed that these relationships were non-linear (all p < 0.05). Kaplan-Meier analysis of data from patients who engaged in 10-450 min/week moderate/vigorous PA revealed significant differences between the 0-74-min/week and other vigorous PA groups (all log-rank p < 0.001).
CONCLUSIONS: Extended durations of vigorous PA are associated with reduced all-cause mortality in overweight/obese patients with CKD. Clinicians should recommend vigorous free-time PA to these patients, and public health interventions should target this goal to maximize patient health.
Fluorescein angiography (FA) has long been the gold standard for vascular imaging of the retina and choroid. It is a test that involves the intravenous injection of fluorescein dye, followed by imaging of the dye's passage through the blood vessels inside the eye. It is commonly used to diagnose many forms of retinovascular disease, as well as to assess the retina's response to various therapeutic interventions. While FA is a relatively safe diagnostic test, it carries the risk of both minor and major side effects. These include nausea and vomiting, yellowing of the skin and urine, vascular extravasation with skin eruption and necrosis, vasovagal reactions, myocardial infarction, respiratory failure, anaphylaxis, cardiopulmonary arrest, and death. Additionally, the test is time-consuming, technically difficult to perform, and requires patients to undergo the discomfort associated with intravenous access. Despite these drawbacks, FA is still commonly used in clinical practice, as there are no existing alternative tests with the ability to provide comparable detail of the retinal and choroidal vasculature.

Phase-variance optical coherence tomography is a novel, noninvasive, software-based technology capable of generating angiographic images from the data gathered by standard OCT scans. Preliminary research suggests it can produce high-definition representations of the retinal and choroidal vasculature which may be more detailed than the images produced by FA.
PURPOSE: A method for improving treatment effect of cancer cells is provided to suppress T cell activation and to enhance sensitivity of cancer cell on conventional anticancer drug. CONSTITUTION: A method for enhancing cancer treatment effect by knock-down of B7-H4 gene in cancer cells comprises: a step of preparing a vector expressing RNAi which is homologous with B7-H4 nucleic acid or B7-H4 gene sequence (Gene bank access No NM 024626) nucleic acid; and a step of transforming cancer cells with the vector. The RNAi is siRNA(small intefering RNA), shRNA(short hairpin RNA), or antisense nucleic acid. The vector is plamid, phage, or virus. The vector is lentivirus. The cancer cells are breast cancer(SK-BR3, KCLB No 30030), uterine cancer cells (HeLa, KCLB No 10002), liver cancer SNU 475 (KCLB No 00475), SNU 423 (KCLB No 00423), SNU 398 (KCLB No 00398), or Hur 7(KCLB 60104).
Cyclosporine; oral or IV route of administration, per investigator discretion. Duration of administration up to 14 days, as tolerated.
Infants randomized to receive BCG-Bulgaria at discharge from the Maternity Ward will receive one 0.05 ml infant dose of Mycobacterium bovis BCG live-attenuated BCG-Bulgaria vaccine by intradermal injection in the left deltoid region. Dependent on national supply, oral polio vaccine will be co-administered.
The present invention provides a skin treating composition comprising caffeine in the form of a coffee seed extract (such as an oil) in combination with a skin moisturizing agent. The extract may comprise caffeine extracted from a green and/or unroasted coffee bean and an antioxidant. Further plant extract(s) having antioxidant, an anti-inflammatory, and antifungal, or an antibacterial properties may be included. To that end, one or more tocopherols having vitamin E activity may be included. Other plants extracts may be added including a butter extract of a plant of the genus  Cacao  or  Butyrospermum , an extract of a seed or a fruit of a plant of the genus  Cocos, Vitis, Prunus , an extract of a plant of the genus  Aloe , or an extract of a plant of the genus  Glycyrrhiza . The composition may further comprise squalene or squalene. The compositions are for improving the level of hydration, condition and appearance of human skin.
PURPOSE:To obtain a strongly bonded ceramics composite by a simple process, by inserting at least a part of a dense molded body in the hole of a porous molded body to simultaneously bake both of them. CONSTITUTION:As ceramics, for example, calcium phosphate type ceramics excellent in bio-compatibility represented by hydroxyapatite are especially suitable. The ceramics powder is molded into a predetermined shape to form a dense molded body 1 while a porous molded body 21 is formed from the ceramics powder and a hole 22 is formed to the porous molded body 21 and at least a part of the aforementioned dense molded body is inserted in said hole 22. Baking temp. is pref. slightly higher than the temp. usually employed in the baking of ceramics and, for example, in the case of the calcium phosphate ceramics, 1,000 deg.C or more is pref. employed and, more pref., about 1,200 deg.C is employed. The post 13 of the dense molded body 11 is inserted in the hole 22 of the porous molded body 21 and both of them are simultaneously baked at 1,200 deg.C in this state to obtain a dense-porous hydroxyapatite composite.
In clinical studies, treatment with 60 mg of Prolia resulted in reduction in the bone resorption marker serum type 1 C-telopeptide (CTX) by approximately 85% by 3 days, with maximal reductions occurring by 1 month. CTX levels were below the limit of assay quantitation (0.049 ng/mL) in 39% to 68% of patients 1 to 3 months after dosing of Prolia. At the end of each dosing interval, CTX reductions were partially attenuated from a maximal reduction of ≥ 87% to ≥ 45% (range: 45% to 80%), as serum denosumab levels diminished, reflecting the reversibility of the effects of Prolia on bone remodeling. These effects were sustained with continued treatment. Upon reinitiation, the degree of inhibition of CTX by Prolia was similar to that observed in patients initiating Prolia treatment.

Consistent with the physiological coupling of bone formation and resorption in skeletal remodeling, subsequent reductions in bone formation markers (i.e., osteocalcin and procollagen type 1 N-terminal peptide [P1NP]) were observed starting 1 month after the first dose of Prolia. After discontinuation of Prolia therapy, markers of bone resorption increased to levels 40% to 60% above pretreatment values but returned to baseline levels within 12 months.
Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
Combating Social Isolation (CSI). CSI and a similar version of this intervention called "Building Stronger Allies", has gone through a rigorous treatment development phase, pilot RCT, and larger RCTs (Schmidt et al., 2014; Schmidt et al., 2017; Schmidt et al., 2007; Norr et al., 2017; Short et al., 2015; Short et al., 2017a; Schmidt et al., submitted for publication). CSI is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated perceived burdensomeness (PB) and thwarted belongingness (TB). The CSI intervention was designed in consultation with clinicians experienced in treating individuals dealing with issues related to PB/TB. CSI is a fully computerized, 1-hour intervention. The latest version of CSI uses Vyond software for video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension). Procedures draw heavily on standard CBT techniques.
OBJECTIVES: End-stage congenital heart disease (CHD) in children with heterotaxy syndrome might necessitate a heart transplant (HTx). An HTx in heterotaxy patients can be associated with several technical (e.g. redo, systemic/pulmonary-venous/situs anomalies, pulmonary artery reconstruction) and extra-cardiac (e.g. ciliary dyskinesia, infections, gastrointestinal) challenges. Our goal was to determine if heterotaxy syndrome is associated with increased early or late transplant risks.
METHODS: The United Network for Organ Sharing transplant database was merged with the Paediatric Health Information System administrative database to identify children with heterotaxy who received an HTx. Characteristics and outcomes were compared between children with heterotaxy and contemporaneous non-heterotaxy congenital and non-congenital cardiomyopathy control groups.
RESULTS: After we merged the databases, we divided our cohort of 1122 patients into 3 groups: the heterotaxy (n = 143), group the non-heterotaxy congenital (n = 428) group and the cardiomyopathy (n = 551) group. There were differences in the characteristics between the 3 groups, with the heterotaxy group being comparable to the non-heterotaxy congenital group. The waiting list duration was longer for the heterotaxy than for the non-heterotaxy congenital and cardiomyopathy groups (91 vs 63 vs 56 days, P < 0.001). Early post-transplant complications were similar for all groups except for operative mortality, which was 1% for the cardiomyopathy and 4% for the heterotaxy and non-heterotaxy congenital groups (P < 0.001). The post-transplant hospital stay was shorter for the cardiomyopathy (57 days) compared to the non-heterotaxy congenital (99 days) and heterotaxy (89 days) groups (P < 0.001). Whereas rejection prior to discharge was comparable between the heterotaxy and the CHD groups, it was higher at 1 year for the heterotaxy (22%) than for the non-heterotaxy congenital (19%) and cardiomyopathy (13%) groups (P < 0.001). Survival at 5 years was superior for the cardiomyopathy (87%) compared to the heterotaxy (69%) and non-heterotaxy congenital groups (78%) (P < 0.001). For the heterotaxy group, no risk factors affecting survival were identified on multivariable analysis.
CONCLUSIONS: Regardless of the complexity, an HTx in selected children with heterotaxy is associated with good mid-term outcomes. Despite early results that are comparable to those of other patients with CHD, the increasing rejection rate at 1 year and the relatively accelerated attrition at mid-term warrant further follow-up. Due to database limitations in defining morphologic and surgical details, further work is warranted to delineate anatomical and surgical variables that could affect survival.